A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Dexcom Inc stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 22,578 shares of DXCM stock, worth $2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
22,578
Previous 56,758 60.22%
Holding current value
$2 Million
Previous $6.44 Million 76.49%
% of portfolio
0.02%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$64.0 - $116.06 $2.19 Million - $3.97 Million
-34,180 Reduced 60.22%
22,578 $1.51 Million
Q2 2024

Aug 13, 2024

BUY
$110.31 - $140.45 $1.86 Million - $2.37 Million
16,886 Added 42.35%
56,758 $6.44 Million
Q1 2024

May 15, 2024

BUY
$114.22 - $140.1 $2.12 Million - $2.6 Million
18,549 Added 86.99%
39,872 $5.53 Million
Q4 2023

Feb 13, 2024

SELL
$75.49 - $124.16 $6.76 Million - $11.1 Million
-89,584 Reduced 80.77%
21,323 $2.65 Million
Q3 2023

Nov 13, 2023

SELL
$86.06 - $137.93 $2.78 Million - $4.46 Million
-32,332 Reduced 22.57%
110,907 $10.3 Million
Q2 2023

Aug 11, 2023

BUY
$112.47 - $130.98 $1.48 Million - $1.73 Million
13,172 Added 10.13%
143,239 $18.4 Million
Q1 2023

May 10, 2023

BUY
$104.0 - $122.92 $702,520 - $830,324
6,755 Added 5.48%
130,067 $15.1 Million
Q4 2022

Feb 13, 2023

BUY
$84.98 - $122.67 $42,574 - $61,457
501 Added 0.41%
123,312 $14 Million
Q3 2022

Nov 14, 2022

SELL
$76.35 - $94.18 $560,179 - $690,998
-7,337 Reduced 5.64%
122,811 $9.89 Million
Q2 2022

Aug 12, 2022

BUY
$67.99 - $132.89 $6.71 Million - $13.1 Million
98,657 Added 313.29%
130,148 $9.7 Million
Q1 2022

May 10, 2022

SELL
$94.08 - $130.2 $554,695 - $767,659
-5,896 Reduced 15.77%
31,491 $16.1 Million
Q4 2021

Feb 11, 2022

BUY
$129.87 - $162.82 $4.86 Million - $6.09 Million
37,387 New
37,387 $20.2 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $34.3B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track B. Metzler Seel. Sohn & Co. Ag Portfolio

Follow B. Metzler Seel. Sohn & Co. Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.